Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 3;13(5):427. doi: 10.1038/s41419-022-04857-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A–C Mining the public dataset (LUAD-TCGA) showing the differential expression of POU6F1 in LUAD patients with different status of death (A), stage (B), and metastasis (C). D Homogeneity of variance analysis revealing the trend of POU6F1 expression in different tumor stages of LUAD patients. E Kaplan–Meier survival curve indicating overall survival (OS) and relapse-free survival (RFS) of LUAD patients with high or low levels of POU6F1 in the GEO dataset (GEO31210). F, G Pooled hazard ratios (HRs) based on univariate analysis (F) and multivariate analysis (G) for assessing the prognostic value of POU6F1 in LUAD patients. H Western blotting assay showing the expression of POU6F1 in human LUAD tissues and adjacent normal tissues (n = 12). Relative expression (H right panel) of POU6F1 was normalized to that of β-actin using ImageJ software. I Real-time qRT-PCR assay showing the expression of POU6F1 in LUAD tissues and adjacent normal tissues (n = 19).